Clinical Trial Update: Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the antitussive effects of FP01 lozenges in subjects with cough due to upper respiratory tract infection has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• FP01 Lozenges (FP01)

Snippet

Sponsor: Avalo Therapeutics, Inc. | Conditions: Acute Cough | Phase 2 | Status: COMPLETED